Cargando…

Glucagon-Like Peptide-2 Ameliorates Age-Associated Bone Loss and Gut Barrier Dysfunction in Senescence-Accelerated Mouse Prone 6 Mice

INTRODUCTION: Senile osteoporosis is one of the most common age-related diseases worldwide. Glucagon like peptide-2 (GLP-2), a naturally occurring gastrointestinal peptide, possesses therapeutic effects on bone loss in postmenopausal women and ovariectomized rats. However, the role of GLP-2 in senil...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yan-Mei, Xu, Bing'er, Kuai, Zheng, He, Yu-Ting, Lu, Yi, Shen, Ji-Ping, Wu, Ke-Fen, Wu, Jia-Yu, Ren, Wei-Ying, Hu, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137319/
https://www.ncbi.nlm.nih.gov/pubmed/36470214
http://dx.doi.org/10.1159/000527502
_version_ 1785032434941689856
author Huang, Yan-Mei
Xu, Bing'er
Kuai, Zheng
He, Yu-Ting
Lu, Yi
Shen, Ji-Ping
Wu, Ke-Fen
Wu, Jia-Yu
Ren, Wei-Ying
Hu, Yu
author_facet Huang, Yan-Mei
Xu, Bing'er
Kuai, Zheng
He, Yu-Ting
Lu, Yi
Shen, Ji-Ping
Wu, Ke-Fen
Wu, Jia-Yu
Ren, Wei-Ying
Hu, Yu
author_sort Huang, Yan-Mei
collection PubMed
description INTRODUCTION: Senile osteoporosis is one of the most common age-related diseases worldwide. Glucagon like peptide-2 (GLP-2), a naturally occurring gastrointestinal peptide, possesses therapeutic effects on bone loss in postmenopausal women and ovariectomized rats. However, the role of GLP-2 in senile osteoporosis and underlying mechanisms has not been explored. METHODS: GLP-2 was subcutaneously injected into the 6-month-old male senile osteoporosis model of senescence-accelerated mouse prone 6 (SAMP6) mice for 6 weeks. SAMP6 subjected to normal saline and senescence-accelerated mouse resistant 1 served as control groups. Micro-computed tomography was performed to evaluate the bone mass and microarchitecture of the mice. Osteoblastic and osteoclastic activities were determined by biochemical, quantitative real-time PCR, histological, and histomorphometric analyses combined with hematoxylin-eosin, toluidine blue, and tartrate-resistant acid phosphatase staining. We also examined the proteins and structure of intestinal tight junction using immunohistochemical assay as well as a transmission electron microscope. Serum inflammation marker levels were measured using ELISA. Additionally, anti-oxidative enzymes GPX-4 and SOD-2 and receptors of GLP-2 and vitamin D expression in the ileum and colon were detected under immunofluorescence staining. RESULTS: Six-week GLP-2 treatment attenuated bone loss in SAMP6 mice, as evidenced by increased bone mineral density, improved microarchitecture in femora, and enhanced osteogenic activities. In contrast, the activity of osteoclastic activity was not obviously inhibited. Moreover, GLP-2 ameliorated tight junction structure and protein expression in the intestinal barrier, which was accompanied by the reduction of TNF-α level. The expression of receptors of intestinal GLP-2 and vitamin D in the ileum was elevated. Furthermore, the oxidative stress in the intestines was improved by increasing the GPX-4 and SOD-2 signaling. CONCLUSION: Our findings suggest that GLP-2 could ameliorate age-associated bone loss, tight junction structure, and improved antioxidant enzyme activity in the gut in SAMP6 mice. Amelioration of gut barrier dysfunction may potentially contribute to improving bone formation and provide evidence for targeting the entero-bone axis in the treatment of senile osteoporosis.
format Online
Article
Text
id pubmed-10137319
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-101373192023-04-28 Glucagon-Like Peptide-2 Ameliorates Age-Associated Bone Loss and Gut Barrier Dysfunction in Senescence-Accelerated Mouse Prone 6 Mice Huang, Yan-Mei Xu, Bing'er Kuai, Zheng He, Yu-Ting Lu, Yi Shen, Ji-Ping Wu, Ke-Fen Wu, Jia-Yu Ren, Wei-Ying Hu, Yu Gerontology Experimental Section: Research Article INTRODUCTION: Senile osteoporosis is one of the most common age-related diseases worldwide. Glucagon like peptide-2 (GLP-2), a naturally occurring gastrointestinal peptide, possesses therapeutic effects on bone loss in postmenopausal women and ovariectomized rats. However, the role of GLP-2 in senile osteoporosis and underlying mechanisms has not been explored. METHODS: GLP-2 was subcutaneously injected into the 6-month-old male senile osteoporosis model of senescence-accelerated mouse prone 6 (SAMP6) mice for 6 weeks. SAMP6 subjected to normal saline and senescence-accelerated mouse resistant 1 served as control groups. Micro-computed tomography was performed to evaluate the bone mass and microarchitecture of the mice. Osteoblastic and osteoclastic activities were determined by biochemical, quantitative real-time PCR, histological, and histomorphometric analyses combined with hematoxylin-eosin, toluidine blue, and tartrate-resistant acid phosphatase staining. We also examined the proteins and structure of intestinal tight junction using immunohistochemical assay as well as a transmission electron microscope. Serum inflammation marker levels were measured using ELISA. Additionally, anti-oxidative enzymes GPX-4 and SOD-2 and receptors of GLP-2 and vitamin D expression in the ileum and colon were detected under immunofluorescence staining. RESULTS: Six-week GLP-2 treatment attenuated bone loss in SAMP6 mice, as evidenced by increased bone mineral density, improved microarchitecture in femora, and enhanced osteogenic activities. In contrast, the activity of osteoclastic activity was not obviously inhibited. Moreover, GLP-2 ameliorated tight junction structure and protein expression in the intestinal barrier, which was accompanied by the reduction of TNF-α level. The expression of receptors of intestinal GLP-2 and vitamin D in the ileum was elevated. Furthermore, the oxidative stress in the intestines was improved by increasing the GPX-4 and SOD-2 signaling. CONCLUSION: Our findings suggest that GLP-2 could ameliorate age-associated bone loss, tight junction structure, and improved antioxidant enzyme activity in the gut in SAMP6 mice. Amelioration of gut barrier dysfunction may potentially contribute to improving bone formation and provide evidence for targeting the entero-bone axis in the treatment of senile osteoporosis. S. Karger AG 2023-04 2022-12-05 /pmc/articles/PMC10137319/ /pubmed/36470214 http://dx.doi.org/10.1159/000527502 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
spellingShingle Experimental Section: Research Article
Huang, Yan-Mei
Xu, Bing'er
Kuai, Zheng
He, Yu-Ting
Lu, Yi
Shen, Ji-Ping
Wu, Ke-Fen
Wu, Jia-Yu
Ren, Wei-Ying
Hu, Yu
Glucagon-Like Peptide-2 Ameliorates Age-Associated Bone Loss and Gut Barrier Dysfunction in Senescence-Accelerated Mouse Prone 6 Mice
title Glucagon-Like Peptide-2 Ameliorates Age-Associated Bone Loss and Gut Barrier Dysfunction in Senescence-Accelerated Mouse Prone 6 Mice
title_full Glucagon-Like Peptide-2 Ameliorates Age-Associated Bone Loss and Gut Barrier Dysfunction in Senescence-Accelerated Mouse Prone 6 Mice
title_fullStr Glucagon-Like Peptide-2 Ameliorates Age-Associated Bone Loss and Gut Barrier Dysfunction in Senescence-Accelerated Mouse Prone 6 Mice
title_full_unstemmed Glucagon-Like Peptide-2 Ameliorates Age-Associated Bone Loss and Gut Barrier Dysfunction in Senescence-Accelerated Mouse Prone 6 Mice
title_short Glucagon-Like Peptide-2 Ameliorates Age-Associated Bone Loss and Gut Barrier Dysfunction in Senescence-Accelerated Mouse Prone 6 Mice
title_sort glucagon-like peptide-2 ameliorates age-associated bone loss and gut barrier dysfunction in senescence-accelerated mouse prone 6 mice
topic Experimental Section: Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137319/
https://www.ncbi.nlm.nih.gov/pubmed/36470214
http://dx.doi.org/10.1159/000527502
work_keys_str_mv AT huangyanmei glucagonlikepeptide2amelioratesageassociatedbonelossandgutbarrierdysfunctioninsenescenceacceleratedmouseprone6mice
AT xubinger glucagonlikepeptide2amelioratesageassociatedbonelossandgutbarrierdysfunctioninsenescenceacceleratedmouseprone6mice
AT kuaizheng glucagonlikepeptide2amelioratesageassociatedbonelossandgutbarrierdysfunctioninsenescenceacceleratedmouseprone6mice
AT heyuting glucagonlikepeptide2amelioratesageassociatedbonelossandgutbarrierdysfunctioninsenescenceacceleratedmouseprone6mice
AT luyi glucagonlikepeptide2amelioratesageassociatedbonelossandgutbarrierdysfunctioninsenescenceacceleratedmouseprone6mice
AT shenjiping glucagonlikepeptide2amelioratesageassociatedbonelossandgutbarrierdysfunctioninsenescenceacceleratedmouseprone6mice
AT wukefen glucagonlikepeptide2amelioratesageassociatedbonelossandgutbarrierdysfunctioninsenescenceacceleratedmouseprone6mice
AT wujiayu glucagonlikepeptide2amelioratesageassociatedbonelossandgutbarrierdysfunctioninsenescenceacceleratedmouseprone6mice
AT renweiying glucagonlikepeptide2amelioratesageassociatedbonelossandgutbarrierdysfunctioninsenescenceacceleratedmouseprone6mice
AT huyu glucagonlikepeptide2amelioratesageassociatedbonelossandgutbarrierdysfunctioninsenescenceacceleratedmouseprone6mice